"Zoetis Stock Plummets Amid Concerns Over Pet Arthritis Drugs Sickening Dogs and Cats"

Zoetis Inc's stock plummeted after reports suggested that its pet arthritis drugs, Librela and Solensia, may have caused adverse effects in dogs and cats. The FDA approved these drugs for pain associated with osteoarthritis in pets, marking a significant development in pet healthcare. However, some pet owners have linked the drugs to adverse effects and deaths in their pets, leading to scrutiny and thousands of reports of side effects. Zoetis stated that these side effects represent a fraction of the shots given and that neither the company nor researchers have identified a connection between the drugs and the reported adverse effects. Additionally, the European Commission initiated an investigation into whether Zoetis hindered the market launch of a competing pain medication for dogs.